{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:41:55Z","timestamp":1774644115140,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T00:00:00Z","timestamp":1385769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12185-013-1480-z","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T23:51:35Z","timestamp":1385682695000},"page":"87-90","source":"Crossref","is-referenced-by-count":21,"title":["Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation"],"prefix":"10.1007","volume":"99","author":[{"given":"Weiyi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baode","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"1480_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"1480_CR2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","volume":"315","author":"E Shtivelman","year":"1985","unstructured":"Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550\u20134.","journal-title":"Nature"},{"key":"1480_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673\u201383.","journal-title":"Nat Rev Cancer"},{"key":"1480_CR4","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2006-12-061135","volume":"109","author":"K Hussein","year":"2007","unstructured":"Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109:4106\u20137.","journal-title":"Blood"},{"key":"1480_CR5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(07)70206-1","volume":"8","author":"A Kramer","year":"2007","unstructured":"Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8:658\u201360.","journal-title":"Lancet Oncol"},{"key":"1480_CR6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404826","volume":"21","author":"M Inami","year":"2007","unstructured":"Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21:1103\u20134.","journal-title":"Leukemia"},{"key":"1480_CR7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","volume":"22","author":"K Hussein","year":"2008","unstructured":"Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22:1059\u201362.","journal-title":"Leukemia"},{"key":"1480_CR8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0609.2008.01063.x","volume":"81","author":"S Pardini","year":"2008","unstructured":"Pardini S, Fozza C, Contini S, Rimini E, Ottaviani E, Amabile M, et al. A case of coexistence between JAK2V617F and BCR\/ABL. Eur J Haematol. 2008;81:75\u20136.","journal-title":"Eur J Haematol"},{"key":"1480_CR9","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.leukres.2009.06.011","volume":"33","author":"L Campiotti","year":"2009","unstructured":"Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res. 2009;33:e212\u20133.","journal-title":"Leuk Res"},{"key":"1480_CR10","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.leukres.2009.08.009","volume":"34","author":"G Caocci","year":"2010","unstructured":"Caocci G, Atzeni S, Orru N, Littera R, Culurgioni F, Marongiu F, et al. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. Leuk Res. 2010;34:e27\u20139.","journal-title":"Leuk Res"},{"key":"1480_CR11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3960\/jslrt.52.145","volume":"52","author":"K Inokuchi","year":"2012","unstructured":"Inokuchi K, Yamaguchi H, Tamai H, Dan K. Disappearance of both the BCR\/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia. J Clin Exp Hematop. 2012;52:145\u20137.","journal-title":"J Clin Exp Hematop"},{"key":"1480_CR12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"1480_CR13","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood-2012-11-467787","volume":"121","author":"X Wang","year":"2013","unstructured":"Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, et al. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood. 2013;121:1238\u20139.","journal-title":"Blood"},{"key":"1480_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3343\/alm.2013.33.3.229","volume":"33","author":"SH Park","year":"2013","unstructured":"Park SH, Chi HS, Cho YU, Jang S, Park CJ, Kim DY, et al. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR\/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment. Ann Lab Med. 2013;33:229\u201332.","journal-title":"Ann Lab Med"},{"key":"1480_CR15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-008-0131-2","volume":"88","author":"MR Conchon","year":"2008","unstructured":"Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol. 2008;88:243\u20135.","journal-title":"Int J Hematol"},{"key":"1480_CR16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2162-3619-2-24","volume":"2","author":"F Pastore","year":"2013","unstructured":"Pastore F, Schneider S, Christ O, Hiddemann W, Spiekermann K. Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol. 2013;2:24.","journal-title":"Exp Hematol Oncol"},{"key":"1480_CR17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.21296","volume":"84","author":"S Gattenlohner","year":"2009","unstructured":"Gattenlohner S, Volker HU, Etschmann B, Einsele H, Muller-Hermelink HK. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome\/myeloproliferative neoplasm (RARS-T). Am J Hematol. 2009;84:306\u20137.","journal-title":"Am J Hematol"},{"key":"1480_CR18","first-page":"34","volume":"6","author":"I Ursuleac","year":"2013","unstructured":"Ursuleac I, Colita A, Adam T, Jardan C, Ilea A, Coriu D. The concomitant occurrence of JAK2V617F mutation and BCR\/ABL transcript with phenotypic expression\u2014an overlapping myeloproliferative disorder or two distinct diseases?\u2014case report. J Med Life. 2013;6:34\u20137.","journal-title":"J Med Life"},{"key":"1480_CR19","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.3816\/CLM.2009.n.080","volume":"9","author":"SR Pingali","year":"2009","unstructured":"Pingali SR, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma. 2009;9:E25\u20139.","journal-title":"Clin Lymphoma Myeloma"},{"key":"1480_CR20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s12185-013-1326-8","volume":"97","author":"YJ Lee","year":"2013","unstructured":"Lee YJ, Moon JH, Shin HC, Seo JW, Han SA, Seo SK, et al. Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. Int J Hematol. 2013;97:804\u20137.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1480-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-013-1480-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1480-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:11:15Z","timestamp":1559437875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-013-1480-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1480-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,30]]}}}